Mindset Pharma Inc (CSE:MSET) CEO James Lanthier tells Proactive the Toronto-based group is preparing its 'next-gen' psilocybin for the clinic, all the while seeing 'quite a bit of interest' from larger psychedelic-focused firms on its portfolio of drug candidates. Lanthier will share more about the group's story at KCSA Strategic Communications' Psychedelic Investor Conference on January 26th - 27th.
Mindset Pharma preparing its 'next-gen' psilocybin for the clinic
